Effect of anticoagulation therapy on bleeding and thromboembolic events (TEs) in the AVADO phase III study of docetaxel (D) bevacizurnab (BV) in inoperable locally recurrent (LR) or metastatic breast cancer (mBC)

被引：0
|
作者：
Wardley, A.
Lohrisch, C.
Joy, A. A.
Young, S.
Yi, F. F.
Marme, A.
Dreosti, L.
Albanell, J.
Munoz, M.
Miles, D. W.
机构：
[1] Christie Hosp, Manchester, Lancs, England
[2] BC Canc Agcy, Vancouver, BC, Canada
[3] Univ Alberta, Cross Canc Inst, Edmonton, AB, Canada
[4] Hop Reg Sudbury Reg Hosp, Sudbury, ON, Canada
[5] Peking Union Med Coll, Beijing 100021, Peoples R China
[6] Chinese Acad Med Sci, Beijing 100037, Peoples R China
[7] Univ Tubingen, Tubingen, Germany
[8] Univ Pretoria, ZA-0002 Pretoria, South Africa
[9] Hosp del Mar, Barcelona, Spain
[10] Hosp Clin Barcelona, Barcelona, Spain
[11] Mt Vernon Canc Ctr, Middlesex, England
来源：
CANCER RESEARCH | 2009年 / 69卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：116S / 116S
页数：1
相关论文
共 50 条
  • [41] Preliminary safety results from PERUSE, a study of 1436 patients (pts) treated with first-line pertuzumab (P) combined with trastuzumab (H) and taxane therapy for HER2-positive locally recurrent/metastatic breast cancer (LR/mBC)
    Miles, D.
    Puglisi, F.
    Schneeweiss, A.
    Ciruelos, E.
    Peretz-Yablonski, T.
    Moreno, K.
    Restuccia, E.
    Lasserre, S.
    Bachelot, T.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S271 - S271
  • [42] A randomized, placebo-controlled phase II study of AMG 386 plus bevacizumab (Bev) and paclitaxel (P) or AMG 386 plus P as first-line therapy in patients (pts) with HER2-negative, locally recurrent or metastatic breast cancer (LR/MBC)
    Dieras, V.
    Jassem, J.
    Dirix, L. Y.
    Guastalla, J. P.
    Bono, P.
    Hurvitz, S. A.
    Goncalves, A.
    Romieu, G.
    Limentani, S. A.
    Jerusalem, G. H. M.
    Lakshmaiah, K.
    Roche, H. H.
    Sanchez-Rovira, P.
    Pienkowski, T.
    Segui-Palmer, M. A.
    Li, A.
    Sun, Y.
    Pickett-Gies, C. A.
    Wildiers, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [43] Progression-free survival. (PFS) in patient subgroups in RIBBON-2, a phase III trial of chemotherapy (chemo) plus or minus bevacizumab (BV) for second-line treatment of HER2-negative, locally recurrent or metastatic breast cancer (MBC).
    Brufsky, A.
    Rivera, R. R.
    Hurvitz, S. A.
    Bondarenko, I. N.
    Smirnov, V.
    Valero, V.
    Rugo, H. S.
    Swamy, R.
    Mu, H.
    Perez, E. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [44] KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab plus chemotherapy vs placebo plus chemotherapy for previously untreated, locally recurrent, inoperable or metastatic triple-negative breast cancer (mTNBC)
    Cortes, Javier
    Guo, Zifang
    Karantza, Vassiliki
    Aktan, Gursel
    CANCER RESEARCH, 2017, 77
  • [45] Combination of Paclitaxel and Bevacizumab without or with Capecitabine as First-Line Treatment of HER2-Negative Locally Recurrent or Metastatic Breast Cancer (LR/MBC): First Results from a Randomized, Multicenter, Open-Label, Phase II Study of the Dutch Breast Cancer Trialists' Group (BOOG).
    Lam, S. W.
    de Groot, S. M.
    Honkoop, A. H.
    Jager, A.
    ten Trje, A. J.
    Bos, M. M. E. M.
    Linn, S. C.
    van den, Bosch J.
    Nortier, J. W. R.
    Braun, J. J.
    de Graaf, H.
    Portielje, J. E. A.
    Los, M.
    Gooyer, D. D.
    van Tinteren, H.
    Boven, E.
    CANCER RESEARCH, 2011, 71
  • [46] Bevacizumab (Bev) combined with either capecitabine (X) or weekly paclitaxel (Pac) as first-line chemotherapy (CT) for HER2-negative, locally recurrent or metastatic breast cancer (LR/MBC): Preliminary safety data from the CECOG phase III TURANDOT trial.
    Lang, I.
    Inbar, M. J.
    Greil, R.
    Steger, G. G.
    Beslija, S.
    Kahan, Z.
    Eniu, A. E.
    Zvirbule, Z.
    Sirbu, D. E.
    Zielinski, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [47] Pertuzumab, trastuzumab, and docetaxel for Chinese patients with previously untreated HER2-positive locally recurrent or metastatic breast cancer (PUFFIN): final analysis of a phase III, randomized, double-blind, placebo-controlled study
    Binghe Xu
    Wei Li
    Qingyuan Zhang
    Qiao Li
    Xiaojia Wang
    Huiping Li
    Tao Sun
    Yongmei Yin
    Hong Zheng
    Jifeng Feng
    Huaqi Zhu
    Asna Siddiqui
    Harrison Macharia
    Adam Knott
    Breast Cancer Research and Treatment, 2023, 197 : 503 - 513
  • [48] Pertuzumab, trastuzumab, and docetaxel for Chinese patients with previously untreated HER2-positive locally recurrent or metastatic breast cancer (PUFFIN): final analysis of a phase III, randomized, double-blind, placebo-controlled study
    Xu, Binghe
    Li, Wei
    Zhang, Qingyuan
    Li, Qiao
    Wang, Xiaojia
    Li, Huiping
    Sun, Tao
    Yin, Yongmei
    Zheng, Hong
    Feng, Jifeng
    Zhu, Huaqi
    Siddiqui, Asna
    Macharia, Harrison
    Knott, Adam
    BREAST CANCER RESEARCH AND TREATMENT, 2023, 197 (03) : 503 - 513
  • [49] Phase III open-label, randomized, multicenter study of NKTR-102 versus treatment of physician's choice (TPC) in patients (pts) with locally recurrent or metastatic breast cancer (MBC) previously treated with an anthracycline, a taxane, and capecitabine (ATC)
    Perez, Edith A.
    Awada, Ahmad
    O'Shaughnessy, Joyce
    Rugo, Hope S.
    Twelves, Christopher
    Cortes, Javier
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [50] Phase III Randomized Study Comparing Docetaxel Plus Trastuzumab With Vinorelbine Plus Trastuzumab As First-Line Therapy of Metastatic or Locally Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: The HERNATA Study
    Andersson, Michael
    Lidbrink, Elisabeth
    Bjerre, Karsten
    Wist, Erik
    Enevoldsen, Kristin
    Jensen, Anders B.
    Karlsson, Per
    Tange, Ulla B.
    Sorensen, Peter G.
    Moller, Susanne
    Bergh, Jonas
    Langkjer, Sven T.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (03) : 264 - 271
12345